Tradestie Institutional Equity Comparison Engine

PAHC vs KTWO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PAHC Overall Edge

PAHC Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Phibro Animal Health Corporation Class A (PAHC) driven by superior Valuation, Growth & Margin, Options & Structure while KTWO counters with relative strength in Momentum & Technical. Fundamentally, PAHC trades at 10.0x Forward P/E with 12.7% operating margin (+6.3% YoY revenue) versus KTWO at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, PAHC sits in CONSOLIDATION (9th %ile IV; Dealer Gamma Walls on Pro) against KTWO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner PAHC
PAHC 10.0x vs KTWO N/M Fwd P/E
Growth & Margin Winner PAHC
Op Margin 12.7% vs N/A ยท YoY +6.3% vs N/A
Momentum & Technical Winner KTWO
1Y -19.6% vs +2.5% ยท 52W Pos 16% vs 97%
Options & Structure Winner PAHC
CONSOLIDATION (9th %ile IV) vs UNCLASSIFIED (N/A IV)
PAHC NASDAQ
Phibro Animal Health Corporation Class A
Pharmaceutical Preparations
$33.29
-2.32% 1D
Market Cap $1.4B
1M Return -16.38%
1Y Return -19.55%
Forward P/E 10.0x
Unified AI Score
65.9 / 100 BUY
Tech 70.0 Fund 65.0 Flow 65.0 Mom 60.0
KTWO US Equity
KTWO
Institutional Equity
$10.12
-0.1% 1D
Market Cap N/A
1M Return +0.2%
1Y Return +2.53%
Forward P/E N/M
Unified AI Score
55.8 / 100 HOLD
Tech 66.0 Fund 57.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: PAHC -19.55% KTWO +2.53% Spread: +38.35 pp (KTWO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
PAHC TTM Op. Margin: 12.7% KTWO TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PAHC vs KTWO. Trailing 12-month operating profitability (PAHC 12.7% vs KTWO N/A) and valuation multiples (PAHC 10.0x vs KTWO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: PAHC (8) vs KTWO (2)
Institutional Metric PAHC KTWO Criterion Row Winner
Market Capitalization Scale $1.4B N/A Larger Scale PAHC
Trailing P/E Ratio Valuation 14.2x N/M Lower Multiple PAHC
Forward P/E Ratio Valuation 10.0x N/M Lower Multiple PAHC
Revenue Growth (YoY) Growth +6.3% N/A Higher Growth PAHC
Operating Margin (TTM) Profitability 12.7% N/A Higher Margin PAHC
Net Profit Margin Profitability 6.7% N/A Higher Margin PAHC
Return on Equity (ROE) Capital Efficiency 28.2% N/A Higher ROE PAHC
52-Week Range Position Momentum 16% ($28โ€“$60) 97% ($10โ€“$10) Stronger Trend KTWO
Beta / 30D Volatility Risk Regime 1.04ฮฒ ยท 55% Vol 0.02ฮฒ ยท 4% Vol Lower Realized Risk KTWO
Unified Institutional Score Composite Signal 65.9 / 100 (BUY) 55.8 / 100 (HOLD) Higher Composite PAHC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full PAHC vs KTWO Buy Guide
PAHC CONSOLIDATION
56d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 9th %ile
IV Regime Compressed (<25th %ile)
Live PAHC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
KTWO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live KTWO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither PAHC nor KTWO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.